21 results about "Heterotopic ossification" patented technology

In part, the present disclosure relates methods for treating heterotopic ossification or one or more complications of heterotopic ossification. In particular, the disclosure provided methods for treating heterotopic ossification by administering to a patient in need thereof one or more TGFβ antagonists, optionally in combination with one or more additional active agents or supportive therapies for treating heterotopic ossification. For example, in some embodiments, the disclosure provided methods for treating heterotopic ossifications by administering to a patient in need thereof an effective amount of a TβRII polypeptide.

The invention relates to the technical field of biomedical materials, in particular to a biomimetic ECM activating factor inflammation response type sustained release microsphere system, which comprises: a) core-shell structure PLGA microspheres, the core of which is loaded with USAG-1 recombinant protein (the drug loading capacity is greater than or equal to 1.5 mu g / mg), and the shell of which is composed of an MMP-9 sensitive peptide crosslinking layer; b) co-modifying nano-hydroxyapatite (nHA) and RGD peptide on the surface of the microsphere, wherein the molar ratio of nHA to RGD is 1: 3; c) uniformly dispersing the BMP-2 in the PLGA matrix to realize zero-order slow-release kinetics; the precise time sequence controlled release and microenvironment responsiveness are as follows: 1) inflammatory stage targeted release: when the local MMP-9 concentration is greater than 15nM, the shell GPLGVRGD peptide crosslinking layer is rapidly degraded (release is greater than or equal to 65% USAG-1 within 24h), premature activation of BMP-2 is inhibited, and the ectopic ossification occurrence rate is reduced from 24.6% to 3.8% (p is less than 0.001); (2) continuously promoting regeneration in a repair period: slowly releasing BMP-2 (53.2 + / -2.1% accumulatively released in 56 days) by a PLGA core through zero-order dynamics, maintaining a stable osteogenesis signal, and increasing the volume ratio of new bones to 58.7% (22.3% of a control group);

Systems for treating a targeted volume of muscle tissue to inhibit heterotopic ossification (HO) employ a delivery device including a reservoir containing a neuromuscular inhibitor and an injector assembly. The injector assembly can include an arrangement of needles and an injector operable to pass the neuromuscular inhibitor from the reservoir through the needles. The injector assembly can be configured to eject predetermined aliquots of a therapeutic dose of the neuromuscular inhibitor. The injector assembly can be shaped to compliment the targeted volume of muscle tissue within a larger volume of muscle tissue. The ejection of the predetermined aliquots can result in a therapeutic distribution of the therapeutic dose of the neuromuscular inhibitor within the targeted volume of muscle tissue that is sufficient to prevent formation of an HO lesion but insufficient to induce paralysis of the larger volume of muscle tissue.

The application discloses a multiple controlled-release drug-loaded coating modified anti-heterotopic ossification artificial temporomandibular joint prosthesis and a preparation method thereof, and comprises the following steps: surface treatment of a biomimetic artificial temporomandibular joint prosthesis; dopamine assisted co-deposition is adopted to sequentially form a DF-HA self-assembled nanosphere coating and a meloxicam liposome drug-loaded coating on the surface of the biomimetic artificial temporomandibular joint porous titanium prosthesis; and RGD is grafted on the surface of the meloxicam liposome drug-loaded coating by chemical natural deposition, and the anti-heterotopic ossification artificial temporomandibular joint prosthesis is obtained. The artificial temporomandibular joint prosthesis is modified by active drug-loaded meloxicam liposomes on one hand, and the artificial temporomandibular joint prosthesis is modified by RGD-DF-HA layered drug loading on the other hand, long-term slow release and programmed release of drugs are realized, anti-inflammatory effects are achieved, the purpose of treating and preventing heterotopic ossification after artificial joint replacement is achieved, long-term stability of artificial joint replacement is beneficial, early prevention, intervention, service life of the artificial joint prosthesis is improved, and the life quality of patients is improved.

To provide a bone morphogenetic protein-9 (BMP-9) variant in which heterotopic ossification side effect is alleviated, and a fusion thereof.SOLUTION: Provided are a bone morphogenetic protein-9 (BMP-9) variant expressed by a specific amino acid sequence, BMP-9 variant-Fc fusion protein in which an Fc fragment of immunoglobulin is connected to the BMP-9 variant, and a pharmaceutical composition for treating cardiopulmonary disease which contains the BMP-9 variant or the BMP-9 variant-Fc fusion protein as an active ingredient. The cardiopulmonary disease is one or more kinds selected from the group consisting of cardiac infarction, hypertension, pulmonary hypertension, myocardial fibrosis, and pulmonary fibrosis.SELECTED DRAWING: Figure 4b

The application discloses application of a near-infrared fluorescent probe WL-808 in preparation of a drug for targeted treatment of heterotopic ossification, wherein the near-infrared fluorescent probe WL-808 can kill chondrocytes loaded with the probe under irradiation of 808 nm excitation light; the energy of photons is transmitted to oxygen through the probe molecules, thereby generating a substance active oxygen (ROS) which is toxic to cells; a large amount of ROS induces chondrocyte apoptosis and extracellular matrix degradation at a heterotopic ossification (HO) lesion site, thereby inhibiting generation of HO chondral and bony lesions, and finally realizing targeted photodynamic treatment of HO.

There is described a compound of formula (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl)benzoic acid or a pharmaceutically acceptable salt thereof or the form A of its sodium salt for use in the prevention of heterotopic ossification. Preferably such a compound is effective in a specific dose range.

The present disclosure provides methods of treating nongenetic heterotopic ossification and other MMP mediated conditions. Such methods are directed to inhibiting active MMP or inhibiting activation of MMP in therapeutic applications. Such methods include use of anti-MMP-9 antibodies directed to inhibiting MMP-9. These methods avoid the deleterious effects of treating nongenetic heterotopic ossification and other MMP mediated conditions with broad spectrum MMP inhibitors.

The present invention belongs to the field of biomedicine, and specifically relates to the use of reagents that knock down or inhibit ANT1 in the preparation of drugs for preventing and / or treating heterotopic ossification. The present invention is the first to discover the use of reagents that knock down or inhibit ANT1 in the preparation of drugs for preventing and / or treating heterotopic ossification. Inhibiting ANT1 can significantly reduce heterotopic ossification formed after soft tissue injury; reduce the infiltration of osteoblasts, chondrocytes, and inflammatory cells in damaged tendons, reduce bone marrow cavity and blood vessel formation, and reduce bone tissue formation; significantly inhibit the expression of osteoblast-related markers OCN, RUNX2, and ALP in injured tendons; and can effectively prevent and / or treat heterotopic ossification.

The invention pertains to the use of glucocorticoid receptor antagonists to prevent heterotopic ossification. Provide herein are methods and uses related to the prophylaxis of heterotopic ossification (HO) in subjects that have experienced an injury or trauma that rely on the administration of a glucocorticoid receptor antagonist. The glucocorticoid receptor antagonist may be an antagonist to cortisol binding the glucocorticoid receptor, such as mifepristone or relacorilant, or a pharmaceutically acceptable salt, derivative, prodrug or solvate thereof.

The application discloses a hydrogel spray for preventing traumatic ectopic ossification, a preparation method and a spraying device. The hydrogel spray comprises photocured hydrogel and nano drug-loaded complex loaded with curcumin, the nano drug-loaded complex is uniformly dispersed in the photocured hydrogel to form the hydrogel spray; the preparation method comprises the process of ultrasonic dispersion of the nano drug-loaded complex in the photocured hydrogel; and the spraying device comprises a spray container containing the hydrogel spray and a spraying head. The hydrogel spray has strong penetration capacity, is convenient to operate, does not cause stimulation to human gastrointestinal tract, and can be used for long-term prevention of traumatic ectopic ossification.

The present disclosure provides methods and compositions for treating non hereditary heterotopic ossification and genetic heterotopic ossification, such as fibrodysplasia ossificans progressive (FOP). Such methods are directed to MMP-9 inhibition in therapeutic applications.

The present invention belongs to the field of medical technology, and in particular relates to the use of halofuginone in the preparation of a drug for treating heterotopic ossification. The present invention provides an application of halofuginone in the preparation of a drug for treating heterotopic ossification. Through imaging observation, histological section staining result observation, and vascular fluorescence staining observation, the positive control group had obvious bone hyperplasia in the Achilles tendon of mice, bone structure formation, obvious cartilage formation in the bone formation area, and obvious blood vessel formation in the Achilles tendon of mice with heterotopic ossification, while the halofuginone-treated group had no obvious bone hyperplasia, no obvious bone formation and cartilage accumulation, and no obvious blood vessel formation in the Achilles tendon of mice with heterotopic ossification. This shows that halofuginone has a good effect of improving bone formation, cartilage accumulation and blood vessel formation, that is, it shows that halofuginone has a good anti-heterotopic ossification effect.

The present invention belongs to the field of biomedicine technology, and specifically relates to a directional spiral stent with the functions of promoting tendon formation and inhibiting ossification, as well as its preparation method and application. The preparation method of the directional spiral stent includes: using ZIF-8 as a delivery carrier of rapamycin to prepare ZIF-8@RAPA; the outer layer uses hexafluoroisopropanol as a solvent, polycaprolactone and type I collagen as solutes; the inner layer uses a mixed solution of dichloromethane and DMF as a solvent, polycaprolactone and ZIF-8@RAPA as solutes; a nanofiber membrane is prepared by electrospinning technology; the nanofiber membrane is mechanically rotated to prepare a directional spiral stent. The directional spiral stent of the present invention can effectively repair tendon damage and inhibit the occurrence of heterotopic ossification. The present invention provides a new option for tendon repair.

The present disclosure provides methods and compositions for treating non hereditary heterotopic ossification and genetic heterotopic ossification, such as fibrodysplasia ossificans progressive (FOP). Such methods are directed to MMP-9 inhibition in therapeutic applications.

This disclosure provides methods and compositions for treating non-hereditary heterotopic ossification and hereditary heterotopic ossification such as progressive ossifying fibrous dysplasia (FOP). These methods involve MMP-9 inhibition in therapeutic applications.

The invention relates to the technical field of biomedical engineering and tissue regeneration, and particularly discloses a functionalized collagen scaffold based on 3D printing and application of the functionalized collagen scaffold in achilles tendon repair and heterotopic ossification prevention. And integrating the CD26 + tendon stem cell exosome which is pretreated by the BMP inhibitor and modified by the collagen binding peptide to form the 3D printing scaffold. According to the invention, the composite scaffold is prepared by integrating a bifunctional strategy of BMP signal inhibition and collagen targeted slow release and combining a 3D printing technology, so that the problems of insufficient regeneration effect and high incidence of heterotopic ossification (HO) in the existing tendon repair technology are obviously solved.

The invention discloses application of lycoris radiata exosomes in preparation of a medicine for treating ectopic ossification, and belongs to the technical field of biological medicine. According to the prepared dried lycoris radiata exosome La-dEXOs, osteoclast differentiation and osteoblast differentiation experiments and animal experiments prove that the prepared La-dEXOs can improve ectopic ossification of rats by promoting osteoclast differentiation and inhibiting osteoblast differentiation. Experimental results show that La-dEXOs has the potential to be developed into related medical products for preventing and treating ectopic ossification.

This disclosure relates to methods and systems for isolating, detecting, and / or analyzing circulating cells and particles, e.g., mesenchyme-derived cells or particles, present in the blood circulation, wherein the methods described herein can be used to determine whether the circulating cells or particles, e.g., mesenchyme-derived cells or particles, are associated with heterotopic ossification (HO). The methods can be used to provide an early diagnosis of HO, thus permitting early intervewntion, and to determine the efficacy of treatment.

The application provides a kind of polypeptide and its application in bone defect repair, belong to polypeptide technical field.The application is based on the functional domain of TGF-beta 3 factor, designs 10 derived peptides, only selects one derived peptide with bone inductive property, the derived peptide is composed of 21 amino acid residues;The polypeptide can not only induce murine bone marrow mesenchymal stem cells to produce mineralization nodule in vitro, but also can induce new bone formation in rat skull extreme bone defect model (in vivo) and rat intramuscular (heterotopic ossification model), and the osteogenic induction efficiency is equivalent to BMP-2.Summing up, the polypeptide provided by the application has bone inductive property, and has great application prospect in bone defect repair.